Clinical trial · Interventional
Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma
Phase II Study Evaluating the Toxicity and Efficacy of a Modified German Paediatric Hodgkin's Lymphoma Protocol (HD95) in Young Adults (Aged 18-30 Years) With Hodgkin's Lymphoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet known which regimen of combination chemotherapy is more effective for Hodgkin lymphoma. PURPOSE: This phase II trial is studying the side effects of three different regimens of combination chemotherapy and to see how well they work in treating younger patients with Hodgkin lymphoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Neurotoxicity | — | UNRESOLVED | — |
Interventions
Interventions (7)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| doxorubicin hydrochloride | Drug | Doxorubicin | ALIAS |
| etoposide | Drug | Etoposide | ALIAS |
| prednisolone | Drug | Prednisolone | ALIAS |
| procarbazine hydrochloride | Drug | Procarbazine | ALIAS |
| radiation therapy | Radiation | — | UNRESOLVED |
| vincristine sulfate | Drug | Vincristine | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Treatment Group 1: stages 1A, 1B, 2A: OEPA x 2
- description
- OEPA (28day cycle): Vincristine 1.5mg/m\^2 iv d1,d8,d15 (capped at 2mg/dose) Etoposide 125mg/m\^2 iv d1-5 Prednisolone 60mg/m\^2 po d1-15 Adriamycin 40mg/m\^2 iv d1 and 15
- interventionNames
- Drug: doxorubicin hydrochloride
- Drug: etoposide
- Drug: prednisolone
- Drug: vincristine sulfate
- Radiation: radiation therapy
- type
- EXPERIMENTAL
- label
- Treatment Group 2: stages 2AE, 2B, 3A: OEPA x 2 + COPP x 2
- description
- OEPA (28 day cycle) Vincristine 1.5mg/m\^2 iv d1,d8,d15 (capped at 2mg/dose) Etoposide 125mg/m\^2 iv d1-5 Prednisolone 60mg/m\^2 po d1-15 Adriamycin 40mg/m\^2 iv d1 and 15 COPP (28 day cycle) Cyclophosphamide 500mg/m\^2 iv d1 and 8 Vincristine 1.5mg/m\^2 iv d1,8 (capped 2mg/dose) Procarbazine 100mg/m\^2 po d1-15\* Prednisolone 40mg/m\^2 po d1-15
- interventionNames
- Drug: cyclophosphamide
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 30 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Biopsy proven de-novo classical Hodgkin lymphoma * Any stage disease * No nodular lymphocyte-predominant Hodgkin lymphoma PATIENT CHARACTERISTICS: * No known or suspected HIV infection * No pre-existing neurological disorder * No serious comorbidity which may prevent administration of study treatment * No other previous malignancy * Not pregnant or nursing * Fertile patients must use effective contraception during and for up to 1 year after completion of study treatment * Creatinine ≤ 1.5 times upper limit of normal (ULN) unless due to the lymphoma * ALT/AST ≤ 1.5 times ULN unless due to the lymphoma * Bilirubin ≤ 2 times ULN unless due to the lymphoma PRIOR CONCURRENT THERAPY: * No prior chemotherapy or radiotherapy * No prior organ transplant
References
Publications (0)
Data not yet available